MY181159A - Sublingual and buccal film compositions - Google Patents

Sublingual and buccal film compositions

Info

Publication number
MY181159A
MY181159A MYPI2015703198A MYPI2015703198A MY181159A MY 181159 A MY181159 A MY 181159A MY PI2015703198 A MYPI2015703198 A MY PI2015703198A MY PI2015703198 A MYPI2015703198 A MY PI2015703198A MY 181159 A MY181159 A MY 181159A
Authority
MY
Malaysia
Prior art keywords
sublingual
film compositions
patient
buccal film
active agent
Prior art date
Application number
MYPI2015703198A
Other languages
English (en)
Inventor
Garry L Myers
Eric Dadey
Original Assignee
Monosol Rx Llc
Aquestive Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monosol Rx Llc, Aquestive Therapeutics Inc filed Critical Monosol Rx Llc
Publication of MY181159A publication Critical patent/MY181159A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2015703198A 2013-03-15 2014-03-14 Sublingual and buccal film compositions MY181159A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/842,543 US20140271788A1 (en) 2013-03-15 2013-03-15 Sublingual and buccal film compositions
US14/196,082 US9511033B2 (en) 2013-03-15 2014-03-04 Sublingual and buccal film compositions

Publications (1)

Publication Number Publication Date
MY181159A true MY181159A (en) 2020-12-19

Family

ID=51528033

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015703198A MY181159A (en) 2013-03-15 2014-03-14 Sublingual and buccal film compositions

Country Status (15)

Country Link
US (5) US20140271788A1 (enExample)
EP (1) EP2968121B1 (enExample)
JP (2) JP6448096B2 (enExample)
KR (1) KR20160029730A (enExample)
CN (1) CN105491997B (enExample)
AU (1) AU2014227693B2 (enExample)
BR (1) BR112015023725A2 (enExample)
CA (1) CA2906773C (enExample)
DK (1) DK2968121T3 (enExample)
IL (1) IL241441B (enExample)
MX (1) MX2015013184A (enExample)
MY (1) MY181159A (enExample)
RU (1) RU2015143647A (enExample)
WO (1) WO2014144241A1 (enExample)
ZA (1) ZA201507685B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271788A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
WO2016105563A1 (en) * 2014-12-23 2016-06-30 Arx, Llc Method of producing uniform buprenorphine-containing formulations
JPWO2016163403A1 (ja) * 2015-04-07 2018-02-01 ニプロ株式会社 経口フィルム製剤
EP3411031B1 (en) 2016-02-04 2024-07-24 CinDome Pharma, Inc. Deuterated domperidone compositions and methods for therapy of disorders
CA3109613A1 (en) 2016-05-28 2017-12-07 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Bio-Technology, Government Of India Uttroside b and derivatives thereof as therapeutics for hepatocellular carcinoma
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2019240212A1 (ja) * 2018-06-14 2019-12-19 株式会社カネカ 薬学的活性成分を含む製剤
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
WO2020006073A1 (en) * 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
GB201819978D0 (en) * 2018-12-07 2019-01-23 Univ Strathclyde Oral thin films
JP7287032B2 (ja) 2019-03-20 2023-06-06 株式会社リコー シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806320B2 (en) 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025147530A1 (en) * 2024-01-05 2025-07-10 Taho Pharmaceuticals Ltd. Naloxone buccal film product and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4366159A (en) 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5223507A (en) 1992-01-21 1993-06-29 G. D. Searle & Co. Method of using opioid compounds as delta opioid selective agonist analgesics
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
ATE214276T1 (de) 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
AT403162B (de) 1995-10-11 1997-11-25 Nycomed Austria Gmbh Neue kristallform von morphin-6-glucuronid
DE19602963A1 (de) 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
CZ297951B6 (cs) 1997-02-14 2007-05-02 Gödecke Aktiengesellschaft Zpusob stabilizace naloxonu
US6372755B2 (en) 1997-07-11 2002-04-16 Toray Industries, Inc. Stable medicinal compositions containing 4,5-epoxymorphinan derivatives
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20140271788A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
EP1648362A4 (en) * 2003-07-01 2012-01-11 Todd Maibach THERAPEUTIC AGENTS WITH FILM
DE602004017514D1 (de) 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US7666442B2 (en) * 2004-08-31 2010-02-23 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
JP2007304673A (ja) 2006-05-09 2007-11-22 Kyocera Mita Corp 監視装置及び監視システム並びに監視プログラム
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
US20170296482A1 (en) 2017-10-19
CA2906773A1 (en) 2014-09-18
IL241441B (en) 2019-07-31
ZA201507685B (en) 2017-06-28
US20140271789A1 (en) 2014-09-18
CA2906773C (en) 2023-12-12
RU2015143647A (ru) 2017-04-21
AU2014227693A1 (en) 2015-10-29
IL241441A0 (en) 2015-11-30
AU2014227693B2 (en) 2018-06-21
US20140271788A1 (en) 2014-09-18
US20190038570A1 (en) 2019-02-07
JP2016513736A (ja) 2016-05-16
MX2015013184A (es) 2016-04-07
EP2968121B1 (en) 2018-12-19
US20200315984A1 (en) 2020-10-08
KR20160029730A (ko) 2016-03-15
EP2968121A1 (en) 2016-01-20
CN105491997A (zh) 2016-04-13
DK2968121T3 (en) 2019-02-04
JP6448096B2 (ja) 2019-01-09
JP2019048882A (ja) 2019-03-28
CN105491997B (zh) 2019-12-17
BR112015023725A2 (pt) 2017-07-18
US9511033B2 (en) 2016-12-06
WO2014144241A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015013184A (es) Composiciones de peliculas sublingual y bucal.
WO2011017484A3 (en) Sublingual and buccal film compositions
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
PH12012500464A1 (en) Sublingual and buccal film compositions
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016008226A (es) Metodos para el cuidado oral prebiotico usando un sacarido.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
TN2016000121A1 (en) Cyclic thienouracil-carboxamides and use thereof
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
IN2014DN09240A (enExample)
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
IN2013MU03428A (enExample)
GB201111427D0 (en) Novel bisindolylmaleimides, pan-pkc inhibitors
MX375398B (es) Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2013006332A (es) Composiciones farmaceuticas orales para uso en dislipidemias.